Suggested Remit: To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for treating Waldenström’s macroglobulinaemia.
Status In progress
Process STA 2018
ID number 1427

Provisional Schedule

Committee meeting: 1 07 September 2021
Expected publication 17 November 2021

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors BeiGene
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
15 February 2021 The timelines for this appraisal have been revised and the first appraisal committee meeting is now scheduled to take place on 7 September 2021. This is to allow the company to address the decision problem in the final scope in its submission.
27 October 2020 Invitation to participate
23 July 2020 - 20 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
31 July 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance